Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...

Untitled Document

Biomerica, Inc. (BMRA)

Listed on the OTC Bulletin Board, Biomerica, Inc. is a global biomedical company. Biomerica develops, manufactures, and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. Biomerica has its corporate headquarters in Irvine, California.

The design of the company’s products is to enhance the health and well being of people, while reducing total healthcare costs. Biomerica mainly concentrates on products for Gastrointestinal Disease, Diabetes, as well as esoteric testing.

The company’s testing kits detect medical problems ranging from allergies, ulcers, and cancer, to infertility and diabetes. Biomerica was the first company to manufacture and market tests for Myoglobin (Cardiac); H. Pylori (Digestive Disease); Histamine (Allergy); a self test for Colon Disease (Digestive); and early detection of Diabetes.

Biomerica’s facility in Irvine, California houses its headquarters, including administrative office, laboratories, and Food and Drug Administration (FDA) registered manufacturing facilities.

Recently, Biomerica reported net sales of $3,467,450 for the nine months ending February 28, 2015, versus $3,441,299 for the same period in the previous year. Sales for the three months ending February 28, 2015 were $1,299,400 versus $1,492,719 for the same period last year.

Net loss for the three months ended February 28, 2015 was $117,193 versus a net income of $26,544 during the same period in fiscal 2014. For the nine months ended February 28, 2015, Biomerica reported a net loss of $574,483 versus a net loss of $384,532 for the same period in the prior fiscal year.

Biomerica has announced the formation of a world class Scientific Advisory Board. This Advisory Board will assist and guide it with the FDA regulatory process for its new gastroenterology product, which is currently patent pending. The new Scientific Advisory Board is being chaired by Mr. Douglas A. Drossman, M.D. The Advisory Board also includes three other key opinion leaders in the field of gastroenterology and Irritable Bowel Syndrome.




The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.